Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 55Central Nervous System Neoplasms 53Brain Neoplasms 48Astrocytoma 30Glioblastoma 27Medulloblastoma 25Glioma 23Oligodendroglioma 21Gliosarcoma 14Optic Nerve Glioma 13Testicular Neoplasms 11Choroid Plexus Neoplasms 11Sarcoma 10Ovarian Neoplasms 10Neoplasms 10Rhabdoid Tumor 9Carcinoma, Non-Small-Cell Lung 9Testicular Germ Cell Tumor 7Teratoma 7Recurrence 7Neuroectodermal Tumors, Primitive, Peripheral 7Familial ependymoma 7Ependymoma 7Lung Neoplasms 6Spinal Cord Neoplasms 5Retinoblastoma 5Osteosarcoma 5Neuroectodermal Tumors, Primitive 5Lymphoma 5Liver Neoplasms 5

Interventions

Bevacizumab 4Temozolomide 3Irinotecan 3Sorafenib 2pembrolizumab 1ibrutinib 1Vorinostat 1Valproic Acid 1Transcranial Magnetic Stimulation 1Therapeutics 1Thalidomide 1Surveys and Questionnaires 1Sildenafil Citrate 1Radiosurgery 1Pliability 1Palliative Care 1Lenalidomide 1Laparoscopy 1Exercise 1Equipment and Supplies 1Carboplatin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurologic Manifestations × Carboplatin × CNS × Clear all
NCT01295944 2025-08-05

Carboplatin and Bevacizumab for Recurrent Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
35 enrolled 17 charts
CNS

Brain Neoplasms, Ependymoma, Neoplasms, Neurologic Manifestations, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡